| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e68a4cd3e0334ccaaf006303614e4aac |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-02 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-1205 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-12 |
| filingDate |
2011-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_91bb49b38c52b7c37b80d50eca28a102
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_98646da7cf1d7d0404e8d39696a96d79 |
| publicationDate |
2011-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2789186-A1 |
| titleOfInvention |
Dual activity kinase domains and uses thereof |
| abstract |
The present invention relates to a dual activity domain JAK proteins, namely JH2. It is provided that the JH2 domain is a true and important target for drug development, especially for diseases caused by aberrant JAK signalling, such as myeloproliferative disorders and leukemias. |
| priorityDate |
2010-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |